Small Molecule Clinical Bioanalysis
Clinical Bioanalysis from First-in-Human Studies Onward
Clinical bioanalysis provides the quantitative data needed to understand small molecule exposure, metabolites, pharmacokinetics, and related biomarkers in human studies. WuXi Biology and Testing supports global clinical trials with validated bioanalytical methods, scalable sample analysis, and coordinated sample management.
Building on discovery and preclinical bioanalysis, we help you carry forward proven analytical approaches while advancing methods to the validation level required for clinical study sample analysis. Method transfer, optimization, full validation, partial validation, and cross-validation can support continuity in assay performance, sample handling, data quality, and reporting as development progresses. Support can be tailored for innovator and generic compounds across early- and later-phase studies.
Clinical PK and LC-MS/MS Quantitation
Measure parent drugs, active moieties, and relevant metabolites in plasma, serum, whole blood, urine, and other clinical matrices using validated LC-MS/MS methods. Clinical PK sample analysis can be scaled to study design, concentration range, sample volume, throughput, and reporting requirements.
Method development, transfer, validation, partial validation, cross-validation, and incurred sample reanalysis can be incorporated as needed to maintain reliable quantitation as the clinical program evolves.
Human Radiolabel Mass Balance and Metabolite Profiling
Extend small molecule clinical bioanalysis beyond routine PK with support for human radiolabeled mass-balance studies, including assessment of absorption, metabolism, excretion, total recovery, and routes of elimination. Clinical metabolite identification and profiling, and cross-species metabolite comparison can be incorporated to characterize circulating and excreted drug-related material.
These data can help clarify metabolic and excretory pathways, characterize metabolite exposure, and support interpretation of the compound’s disposition in humans.
Clinical Biomarker Support
Integrate biomarker measurements with PK and exposure data to support pharmacodynamic, safety, efficacy, and translational objectives. Platform selection is driven by the analyte and intended use rather than by the small-molecule PK workflow alone.
LC-MS/MS can support small-molecule and peptide biomarkers, while ligand-binding assays can support protein biomarkers. Complementary molecular and cell-based approaches may be used when appropriate to the biomarker and study question.
Sample Management and Clinical Study Continuity
Clinical data quality depends on sample integrity from collection through analysis. We support sample receipt, storage, transport coordination, inventory control, and material management to help protect stability and chain of custody throughout the study.
For global and multi-site trials, standardized workflows and method-transfer planning can help maintain comparability as sample volume increases or analysis moves across laboratories. This continuity helps reduce avoidable assay redevelopment and supports consistent clinical reporting.
Explore Solutions for Your Program
Explore solutions by development phase, drug modality, therapeutic area, or integrated discovery needs.
You May Also Be Interested In
Get a Quote
Ready to plan your next study? Share your program needs with our team for a tailored estimate.
Frequently Asked Questions
Small molecule clinical bioanalysis quantitatively measures drugs, metabolites, and relevant biomarkers in biological samples collected during human clinical studies. The data support pharmacokinetic, pharmacodynamic, dose-selection, and safety assessments.
Common matrices include plasma, serum, whole blood, urine, saliva, and other biological fluids. The appropriate matrix depends on the analyte, study design, expected concentration range, stability, and clinical sampling plan.
LC-MS/MS is a primary platform for sensitive and selective quantitation of small molecule drugs and metabolites. Biomarker measurements may use LC-MS/MS, ligand-binding assays, or complementary molecular and cell-based approaches depending on the analyte and intended use.
For clinical drug and metabolite quantitation within the scope of ICH M10, full validation is expected for the primary matrix intended to support regulatory submissions. Partial validation or cross-validation may be needed when methods, matrices, ranges, or laboratories change. Biomarker methods are qualified or validated according to their intended use and applicable requirements.
A human radiolabeled mass-balance study characterizes absorption, metabolism, excretion, recovery, and routes of elimination by tracking drug-related radioactivity in clinical samples, including blood or plasma, urine, and feces. The study can also support metabolite identification and profiling.